Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | XYA02 |
| Synonyms | |
| Therapy Description |
XYA02 is an antibody-drug conjugate (ADC) that targets the membrane-tethered MUC1-C subunit of MUC1, which potentially inhibits tumor growth (Cancer Res (2026) 86 (7_Supplement): 3175). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| XYA02 | XYA-02|XYA 02 | MUC1 Antibody 10 | XYA02 is an antibody-drug conjugate (ADC) that targets the membrane-tethered MUC1-C subunit of MUC1, which potentially inhibits tumor growth (Cancer Res (2026) 86 (7_Supplement): 3175). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07670312 | Phase Ib/II | XYA02 | Evaluation of XYA02 in Patients With Advanced Solid Tumors | Not yet recruiting | AUS | 0 |